Key Takeaways
- • 4BIO Capital leads €40 million ($45 million) seed financing round for Aptadir Therapeutics, a biotech company developing first-in-class RNA-based demethylating medicines for intractable genetic conditions.
- • Aptadir's lead candidate, CAP1-FMR1, targets Fragile X Syndrome using a novel class of RNA inhibitors capable of blocking aberrant DNA methylation at the single-gene level to reverse abnormal gene silencing.
- • Seed round includes follow-on participation from EXTEND (a consortium of CDP Venture Capital SGR, Angelini Ventures, and Evotec SE), Aptadir's original pre-seed investor, indicating sustained institutional confidence in the platform.
- • Scientific foundation originates from three leading research institutions: Beth Israel Deaconess Medical Center, Italy's National Research Council (CNR), and Singapore's Cancer Science Institute, providing multi-institutional validation of the underlying biology.
- • 4BIO Capital positions the investment as addressing "previously entirely undruggable disease mechanisms," signaling potential for a broad pipeline of disease-modifying therapeutics beyond the lead indication.
Summary
Aptadir Therapeutics closed a €40 million seed financing round on September 29, 2026, led by 4BIO Capital, a specialist biotech venture firm focused on precision therapies. The funding will accelerate development of Aptadir's pipeline of disease-modifying RNA therapeutics, with the lead candidate CAP1-FMR1 advancing toward clinical development for Fragile X Syndrome.
Aptadir's platform represents a novel therapeutic modality based on a landmark discovery of a new class of RNA inhibitors capable of blocking aberrant DNA methylation at the single-gene level. The mechanism works by reversing abnormal gene silencing, thereby reactivating gene expression and restoring normal biological function—an effect the company has demonstrated in patient-derived disease models. This approach addresses a previously undruggable class of genetic conditions driven by epigenetic dysfunction.
The seed round demonstrates sustained institutional conviction, with participation from EXTEND, the company's original pre-seed backer comprising CDP Venture Capital SGR, Angelini Ventures, and Evotec SE. The syndication structure suggests confidence from both venture and strategic industry partners in the durability of Aptadir's science and commercial potential.
The company's scientific foundation is anchored in research from three globally recognized institutions: Beth Israel Deaconess Medical Center in the United States, the Italian Research National Council (CNR), and the Cancer Science Institute of Singapore. This multi-institutional pedigree provides validation of the underlying biology and reduces execution risk associated with early-stage therapeutic platforms.
4BIO Capital's Managing Partner Dima Kuzmin characterized the investment decision as backing "truly innovative new science" where "rigorous biology meets real unmet medical need," emphasizing the firm's thesis around novel modalities capable of generating multiple therapeutics from a single platform. For institutional investors tracking emerging RNA therapeutic opportunities and epigenetic drug development, this capitalization event signals material progress in translating foundational science into a potentially transformative therapeutic pipeline.
Aptadir's platform represents a novel therapeutic modality based on a landmark discovery of a new class of RNA inhibitors capable of blocking aberrant DNA methylation at the single-gene level. The mechanism works by reversing abnormal gene silencing, thereby reactivating gene expression and restoring normal biological function—an effect the company has demonstrated in patient-derived disease models. This approach addresses a previously undruggable class of genetic conditions driven by epigenetic dysfunction.
The seed round demonstrates sustained institutional conviction, with participation from EXTEND, the company's original pre-seed backer comprising CDP Venture Capital SGR, Angelini Ventures, and Evotec SE. The syndication structure suggests confidence from both venture and strategic industry partners in the durability of Aptadir's science and commercial potential.
The company's scientific foundation is anchored in research from three globally recognized institutions: Beth Israel Deaconess Medical Center in the United States, the Italian Research National Council (CNR), and the Cancer Science Institute of Singapore. This multi-institutional pedigree provides validation of the underlying biology and reduces execution risk associated with early-stage therapeutic platforms.
4BIO Capital's Managing Partner Dima Kuzmin characterized the investment decision as backing "truly innovative new science" where "rigorous biology meets real unmet medical need," emphasizing the firm's thesis around novel modalities capable of generating multiple therapeutics from a single platform. For institutional investors tracking emerging RNA therapeutic opportunities and epigenetic drug development, this capitalization event signals material progress in translating foundational science into a potentially transformative therapeutic pipeline.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.